Lexicon Pharmaceuticals
LXRX
104 hedge funds and large institutions have $657M invested in Lexicon Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
5% more funds holding
Funds holding: 99 → 104 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less capital invested
Capital invested by funds: $749M → $657M (-$92.1M)
16% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$6.1M |
| 2 |
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
|
+$778K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$186K |
| 4 |
Bank of New York Mellon
New York
|
+$167K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$3.87M |
| 2 |
Axa
Paris,
France
|
-$725K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$380K |
| 4 |
TA
Teton Advisors
Rye,
New York
|
-$302K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$260K |
LXRX Hedge Fund Activity: Q3 2014 in Review
104 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2014, worth a combined $657M — down 12% from $749M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LXRX positions and 7 closed out — a net gain of 5 holders — while 27 added to existing stakes and 32 trimmed.
The largest buyer was UBS AM, adding an estimated $6.1M. The largest seller was Norges Bank, cutting an estimated $3.87M.
- 104 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2014, up from 99 in Q2 2014.
- Funds reported $657M of Lexicon Pharmaceuticals stock for Q3 2014, down 12% quarter-over-quarter.
- 12 funds opened new Lexicon Pharmaceuticals positions in Q3 2014 and 7 closed out, a net change of +5 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2014 was UBS AM, an estimated $6.1M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $3.87M sold.
Based on aggregated 13F filings for Q3 2014.